ербитукс 5мг кутија

Erbitux® 5mg

cetuximab
Summary report on drug properties

Terapeutic indications

Erbitux is indicated for the treatment of patients with epidermal growth factor receptor (EGFR)-expressing, RAS wild-type metastatic colorectal cancer:

  • In combination with irinotecan-based chemotherapy,
  • In 1st line in combination with FOLFOX,
  • As a single agent in patients who have failed oxaliplatin- and irinotecan-based therapy and who are intolerant to irinotecan.

 

Erbitux is indicated for the treatment of patients with squamous cell cancer of the head and neck:

  • In combination with radiation therapy for locally advanced disease,
  • In combination with platinum-based chemotherapy for recurrent and/or metastatic disease.

Choose an indication

Select one of the indications below for more information about the safety and efficacy of Erbitux®

Metastatic colorectal cancer

Squamous cell carcinomas of the head and neck